Worldwide, fungal and microbial diseases are a major cause of mortality and have the capacity to spread like epidemics, which puts a significant financial strain on countries, especially poor ones. These infections can be prevented from spreading long before they become dangerous by isolating infected people and conducting primary screening tests. By the end of 2022, the market for anti-microbial/anti-fungal diagnostics is projected to be valued US$2.5 billion. By 2032, market growth is expected to hit US$ 4.5 billion at a compound annual growth rate of 5.7%. With a market share of about 53.5%, molecular-based tests topped the global anti-microbial test /anti-fungal market size for ten years in 2021, according to test type.
Region – Robust Healthcare Infrastructure in North America Enables Rapid Anti-Microbial/ Anti-Fungal Testing
North America has the largest regional contribution and is predicted to account for approx. a third of the anti-microbial/ anti-fungal tests industry at the end of the forecast period. The North America anti-microbial/ anti-fungal tests market should cross a billion dollars by 2027 – the only region to do so. Most physicians on the continent typically prescribe diagnostics tests before starting any sort of treatment, fuelling demand for anti-microbial/ anti-fungal test kits. Furthermore, there is immense awareness of the side-effects of certain drugs and patients often prefer to get completely diagnosed before seeking treatment.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-5566
Test Type – Molecular Based Tests Critical in Anti-Microbial/ Anti-Fungal Tests Market
Molecular based tests dominated the global anti-microbial/ anti-fungal tests market by test type in 2017 and are likely to retain this commanding position for the foreseeable future. Molecular based tests have a market attractiveness index of 2.6 – considerably higher than all other test types in the anti-microbial/ anti-fungal tests market. Within the molecular based tests segment, companies would be advised to focus their attention on the PCR Test sub-segment as it is roughly thrice the size of DNA microarray tests in terms of value. The PCR test segment is further poised to record a CAGR of 6.4% for the decadal study.
Infection Type – Target Antimicrobial Resistance and Microbial Infection Segments in Anti-Microbial/ Anti-Fungal Tests Market
The antimicrobial and microbial resistance segments are the ones to look out for as they comprise almost 3/4th of the global anti-microbial/ anti-fungal tests market between them. The multi-drug-resistant mycobacterium tuberculosis sub-segment is the largest in the antimicrobial resistance segment and should grow at a high rate as well. Along with multi-drug-resistant mycobacterium tuberculosis, the microbial infection segment holds great potential in the anti-microbial/ anti-fungal tests market as it is on track to push past a value of US$ 1 billion by end 2027.
Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-5566
End User – Hospitals and Reference Labs Demand Antimicrobial/ Antifungal Testing Kits
Hospitals and reference labs are the largest end users in the anti-microbial/ anti-fungal tests market by a substantial margin. It has been observed that the global per-capita healthcare spending has doubled because of rising awareness of myriad treatment options and diagnostic tools for detecting and curing various diseases. Reference labs are predicted to grow faster than hospitals in the anti-microbial/ anti-fungal tests market.
Competition Dashboard in the Anti-Microbial/ Anti-Fungal Tests Market
The companies profiled in the report are Abbott Laboratories, bioMérieux SA, Bio-Rad Laboratories, Bruker Corporation, Danaher Corporation, Erba Mannheim, F. Hoffmann-La Roche AG, Luminex Corporation, Meridian Bioscience, Norgen Biotek Corp., Omega Diagnostics Group Plc., Qiagen N.V., Quidel Corporation, and Thermo Fisher Scientific Inc.
Takeaways
The prevalence and incidence rate of infectious diseases such as diarrhoea and malaria is at an all-time high in Asia and Africa. Governmental and non-governmental organizations such as the WHO are seeking to reduce prevalence rates by early diagnosis through antimicrobial and antifungal kits. In addition to this, government tenders and partnerships with manufacturers is anticipated to provide a steady revenue stream for the latter, growing the anti-microbial/ anti-fungal tests market as a whole.
Why Future Market Insights?
• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years
Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario
Unlock exclusive insights with our expert analysts:
https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-5566
Key Market Segments Covered in Anti-microbial/Anti-fungal Tests Industry Research
By Tests Type:
- Molecular Based Tests
- PCR Test
- DNA Microarray
- Phenotypic Resistance Tests
- Complex Test Panels
- Mass Spectrometry
- Rapid Diagnostic Tests
- E-Test Antibiotic/Antifungal Strips
- Biosensor Platforms
By Infection Type:
- Antimicrobial Resistance
- Methicillin-Resistant Staphylococcus Aureus
- Vancomycin-Resistant Enterococcus
- Multi-Drug-Resistant Mycobacterium tuberculosis
- Carbapenem-Resistant Enterobacteriaceae gut bacteria
- Microbial Infection
- Antifungal Resistance
- Candida infections
- Aspergillus infection
- Fusariosis
- Others
- Fungal Infection
By End User:
- Hospitals
- Ambulatory Surgical Centers
- Clinics
- Community Health Centers
- Reference Laboratories
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
